EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Magnetic resonance‐guided split‐course hypo‐fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non–small cell lung cancer: A single arm, phase 2 study

PengXin Zhang, DaQuan Wang, ShaoHan Yin, YuMei Dong, ShiHong Wei, FangJie Liu iD, HaoTing Zhang, Biao Xia, Yu SiTu, MengRu Wang, Yi Hu, QianWen Liu und 3 weitere

Cancer · 2025

DOI: 10.1002/cncr.70223 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von PengXin Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Pro…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Magnetic Resonance Imaging. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the efficacy and safety of magnetic resonance (MR)‐guided split‐course hypo‐fractionated radiotherapy (hypo‐RT) with concurrent chemotherapy followed by consolidative immunotherapy (CIT) in locally advanced non–small cell lung cancer (LA‐NSCLC).

Methods

In this phase 2 trial, patients with unresectable stage IIIA–C NSCLC (18–75 years old, Eastern Cooperative Oncology Group 0–1) received MR‐guided split‐course hypo‐RT (30 Gy in six fractions, repeated after 4 weeks for a total of 60 Gy) with concurrent weekly docetaxel (25 mg/m 2 ) and cisplatin (25 mg/m 2 ). The primary end point was progression‐free survival (PFS); secondary end points included overall survival (OS), objective response rate (ORR), and toxicities.

Results

Between July 2020 and January 2023, 104 patients were enrolled with a median follow‐up of 34.4 months. Split‐course hypo‐concurrent chemoradiotherapy (CCRT) was completed in 101 (97.1%) patients, and 74 (71.2%) received CIT. The median PFS was 27.5 months (95% confidence interval [CI], 18.9–36.0 months), and the 1‐ and 2‐year PFS rates were 76.9% (95% CI, 69.2%–85.5%) and 54.7% (95% CI, 45.9%–65.1%), respectively. The 1‐ and 2‐year OS were 87.5% (95% CI, 81.4%–94.1%) and 65.3% (95% CI, 56.8%–75.2%), respectively. The most common grade 3–4 adverse event was lymphopenia (35.6%). Grade 2–3 pneumonitis was observed in eight patients (7.7%) during hypo‐CCRT and in seven patients (6.7%) during CIT. Grade 3 esophagitis occurred in three patients (2.8%), and one grade 5 hemoptysis was reported (0.9%).

Conclusion

The MR‐guided split‐course hypo‐CCRT delivered at 5 Gy per fraction to a total dose of 60 Gy followed by CIT yielded encouraging survival outcomes with manageable toxicities in patients with LA‐NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyMagnetic Resonance ImagingAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyRadiotherapy, Image-GuidedHumansMiddle AgedMaleFemaleAgedAdultCisplatinDocetaxelRadiation Dose HypofractionationYoung AdultProgression-Free SurvivalDose Fractionation, Radiation

Stichwörter der Autor:innen

hypofractionated doseimmunotherapymagnetic resonance imagingnon–small cell lung cancerradiotherapy

Substanzen

CisplatinDocetaxel

Autor:innen und Institutionen

  • Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Ca…
  • Department of Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Cent…
  • Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou City, Gansu Province, China.
  • Department of Thoracic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Can…
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Canc…

ORCID-Profile: FangJie Liu, LiKun Chen, Hui Liu

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Zhang, P., Wang, D., Yin, S., Dong, Y., Wei, S., Liu, F., Zhang, H., Xia, B., SiTu, Y., Wang, M., Hu, Y., Liu, Q., Chen, L., Qiu, B., & Liu, H. (2025). Magnetic resonance‐guided split‐course hypo‐fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non–small cell lung cancer: A single arm, phase 2 study. Cancer. https://doi.org/10.1002/cncr.70223

Vancouver

Zhang P, Wang D, Yin S, Dong Y, Wei S, Liu F, et al. Magnetic resonance‐guided split‐course hypo‐fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non–small cell lung cancer: A single arm, phase 2 study. Cancer. 2025. doi:10.1002/cncr.70223

BibTeX
@article{Zhang2025,
  author = {Zhang, PengXin and Wang, DaQuan and Yin, ShaoHan and Dong, YuMei and Wei, ShiHong and Liu, FangJie and Zhang, HaoTing and Xia, Biao and SiTu, Yu and Wang, MengRu and Hu, Yi and Liu, QianWen and Chen, LiKun and Qiu, Bo and Liu, Hui},
  title = {Magnetic resonance‐guided split‐course hypo‐fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non–small cell lung cancer: A single arm, phase 2 study},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70223}
}
Kostenlos starten →